Novo Nordisk’s CagriSema Shows Promising Results in Weight Loss Trial

Novo Nordisk has unveiled promising results from its REDEFINE 2 trial, testing the weight-loss potential of CagriSema, a once-weekly treatment combining cagrilintide and semaglutide. Over the 68-week study, participants with obesity and type 2 diabetes saw an average weight reduction of 15.7%—a stark contrast to the 3.1% loss observed in the placebo group. Nearly 90% of those on CagriSema achieved at least a 5% weight reduction, reinforcing its potential as a breakthrough therapy. Though mild gastrointestinal issues were reported, the treatment was well tolerated overall.

Martin Holst Lange, Novo Nordisk’s Executive Vice President for Development, emphasized the significance of these findings, stating that CagriSema could offer a vital new option for those struggling with obesity and diabetes. With regulatory filing planned for early 2026, the company is optimistic about making this next-generation treatment widely available. Full trial details will be presented at a scientific conference in 2025.